Gray Market Peptides: So Much Hype, So Little Data BPC 157 Banned: Key Facts on the Latest FDA Decision Is BPC 157 Legal? Understanding Its Status and Implications Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide BPC 157: Experimental Peptide Creates Risk for Athletes